Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Trial ID or NCT#
NCT04023552
Status
NOT RECRUITING
Purpose
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Official Title
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Eligibility Criteria
Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Exclusion Criteria:
Investigator(s)
Abha Khandelwal
Cardiologist,
Obstetrics cardiologist
Clinical Associate Professor, Medicine - Cardiovascular Medicine
View on